Boston-based Bicara Therapeutics, a clinical-stage biopharma developing therapies for patients with solid tumors, this week announced the closing of its initial public offering which raised gross proceeds of approximately $362 million. Bicara’s lead asset, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody […]

Moderna used its annual R&D Day to announce program and financial updates demonstrating progress and strategic prioritization of its mRNA pipeline including data readouts in the company’s respiratory vaccine portfolio and a revised financial framework. Over the past three years, Moderna’s robust pipeline has achieved milestones across multiple late-stage clinical trials, and its early-stage portfolio […]

Massachusetts added almost 3,000 net new jobs in the biopharma industry in 2023, accounting for nearly 17% of overall job growth in the state. Meanwhile, the research and development workforce grew by 3.7%, even as the national R&D workforce decreased by 0.5%. This is according to the annual MassBio Industry Snapshot which tracks the state’s life […]